2-[(3R,5S)-4-[2-[(1R)-1-butoxyethyl]pyrimidin-4-yl]-3,5-dimethylpiperazin-1-yl]-4-phenyl-1,3,5-triazine | 474100-13-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[(3R,5S)-4-[2-[(1R)-1-butoxyethyl]pyrimidin-4-yl]-3,5-dimethylpiperazin-1-yl]-4-phenyl-1,3,5-triazine
• CAS: 474100-13-5
• 化学式: C₂₅H₃₃N₇O
• 分子量: 447.583
• InChiKey: HEJIIQIPYUNFRH-HSALFYBXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  80.2
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-[(3R,5S)-4-[2-[(1R)-1-butoxyethyl]pyrimidin-4-yl]-3,5-dimethylpiperazin-1-yl]-4-phenyl-1,3,5-triazine 在 盐酸 作用下， 生成 1-{4-[2,6-Dimethyl-4-(4-phenyl-[1,3,5]triazin-2-yl)-piperazin-1-yl]-pyrimidin-2-yl}-ethanol
  参考文献：
  名称：

  A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a Long Duration of Action:  1-(R)-{4-[4-(4,6-Dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl}ethanol

  摘要：

  We report here a novel sorbitol dehydrogenase inhibitor, 16, that shows very high oral potency (50 mug/kg) in normalizing elevated fructose levels in the sciatic nerve of chronically diabetic rats and sustained duration of action (> 24 h). Furthermore, 16 shows attractive pharmaceutical properties, including good solubility in simulated human gastric fluid, excellent Caco-2 Papp, moderate lipophilicity, and metabolic stability for achieving good oral absorption and long duration of action.

  DOI：

  10.1021/jm020288y
• 作为产物：
  描述：

  2,4-二氯-6-苯基-1,3,5-三嗪 在 palladium on activated charcoal 乙醇 、 氢气 、 碳酸氢钠 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-[(3R,5S)-4-[2-[(1R)-1-butoxyethyl]pyrimidin-4-yl]-3,5-dimethylpiperazin-1-yl]-4-phenyl-1,3,5-triazine
  参考文献：
  名称：

  A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a Long Duration of Action:  1-(R)-{4-[4-(4,6-Dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl}ethanol

  摘要：

  We report here a novel sorbitol dehydrogenase inhibitor, 16, that shows very high oral potency (50 mug/kg) in normalizing elevated fructose levels in the sciatic nerve of chronically diabetic rats and sustained duration of action (> 24 h). Furthermore, 16 shows attractive pharmaceutical properties, including good solubility in simulated human gastric fluid, excellent Caco-2 Papp, moderate lipophilicity, and metabolic stability for achieving good oral absorption and long duration of action.

  DOI：

  10.1021/jm020288y

文献信息

• A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a Long Duration of Action:  1-(<i>R</i>)-{4-[4-(4,6-Dimethyl[1,3,5]triazin-2-yl)- 2<i>R</i>,6<i>S</i>-dimethylpiperazin-1-yl]pyrimidin-2- yl}ethanol
  作者：Banavara L. Mylari、Peter J. Oates、William J. Zembrowski、David A. Beebe、Edward L. Conn、James B. Coutcher、Melissa T. O'Gorman、Michael C. Linhares、Gregory J. Withbroe

  DOI：10.1021/jm020288y

  日期：2002.9.1

  We report here a novel sorbitol dehydrogenase inhibitor, 16, that shows very high oral potency (50 mug/kg) in normalizing elevated fructose levels in the sciatic nerve of chronically diabetic rats and sustained duration of action (> 24 h). Furthermore, 16 shows attractive pharmaceutical properties, including good solubility in simulated human gastric fluid, excellent Caco-2 Papp, moderate lipophilicity, and metabolic stability for achieving good oral absorption and long duration of action.